Therapeutic potential of cannabinoid receptor agonists as analgesic agents

Bibliography

• AMERI A: The effects of cannabinoids on the brain. Frog. Neurobiol (1999) 58:315–348.
   Google Scholar
• HERKENHAM M, LYNN AB, JOHNSON MR, MELVIN LS, DE COSTA BR, RICE KC: Characterisation and localistion of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Neurosci. (1991) 11:563–583.
   PubMed Web of Science ®Google Scholar
• PERT WEE RG: Pharmacology of cannabinoid CBI and CB2 receptors. Phannacol The]: (1997) 74:129–180.
   Web of Science ®Google Scholar
• SCHATZ AR, LEE M, CONDIE RG, PULASKI JT, KAMINSKI NE: Cannabinoid receptors CB and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol App.]. Phannacol (1997) 142:278–287.
   PubMed Web of Science ®Google Scholar
• TSOU K, BROWNS, SANUDO-PENA MC, MacKIE K, WALKER JM: Immunohistochemical distribution of cannabinoid CBI receptors in the rat central nervous system. Neuroscience (1998) 83:393–411.
   PubMed Web of Science ®Google Scholar
• DEUSCH E, KRAFT B, NAHLIK G, WEIGL L, HOHENEGGER M, KRESS HG: No evidence for direct modulatory effects of 49-tetrahydrocannabinol on human polymorphonuclear leukocytes. J. Inununol (2003) 141:99–103.
   Google Scholar
• IHENETU K, MOLLEMANN A, PARSONS M, WHELAN C: Pharmacological characterization of cannabinoid receptors inhibiting interleukin-2 release from human peripheral blood mononuclear cells. Eur. Phamacol (2003) 464:207–215.
   PubMed Web of Science ®Google Scholar
• LAU AHY, CHOW SSM: Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells. Eur Phannacol (2003) 464:229–235.
   PubMed Web of Science ®Google Scholar
• CROXFORD JL: Therapeutic potential of cannabinoids in CNS disease. CNS Drugs (2003) 17:179–202.
   PubMed Web of Science ®Google Scholar
• CRAVATT BE LICHTMAN AH: The endogenous cannabinoid system and its role in nociceptive behavior. J. Neurobiol (2004) 61:149–160.
   PubMedGoogle Scholar
• DEUTSCH DG, GLASER DK, HOWELL JM et al: The cellular uptake of 700Expert Op/n. Investig. Drugs (2005) 14(6) anandamide is coupled to its breakdown by fatty acid amide hydrolase." Biol. Chem. (2001) 276:6967–6973.
   Google Scholar
• RICE ASC: Cannabinoids and pain. Curl: Opin. Invest. Drugs (2001) 2:399–414.
   PubMedGoogle Scholar
• PERTWEE RG, ROSS RA: Canabinoid receptors and their ligands. Prost. Leuk. Ess. Fatty Acids (2002) 66:101–121.
   PubMed Web of Science ®Google Scholar
• KLEIN TW, NEWTON C, LARSEN K et al.: the cannabinoid system and immune modulation. J. Leukoyte Biol. (2003) 74:486–496.
   PubMed Web of Science ®Google Scholar
• SOFIA RD, NALEPA SD, HARAKAL JJ,VASSAR HB: Antiedema and analgesic properties of A9-tetrahydrocannabinol (THC). Pharmacol. Exp. Thar. (1973) 186:646–655.
   PubMed Web of Science ®Google Scholar
• LICHTMAN AH, MARTIN BR: Spinal and supraspinal components of cannabinoid-induced antinociception. Pharmacol Exp. Thar. (1991) 258:517–523.
   PubMed Web of Science ®Google Scholar
• SMITH PB, COMPTON DR, WELCH SP, RAZDAN R, MECHOULAM R, MARTIN BR: The pharmacological activity of anandamide, a putative endogenous cannabinoid in mice. Pharmacol Exp. Thar. (1994) 270:219–227.
   PubMed Web of Science ®Google Scholar
• MARTIN WJ, HOHMANN AG, WALKER JM: Suppression of noxious hstimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects.j Neurosci. (1996) 16:6601–6611.
   PubMed Web of Science ®Google Scholar
• SMITH FL, FUJIMORI K, LOWE J, WELCH SP: Characterisation of A9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem. Behav. (1998) 60:83–191.
   PubMedGoogle Scholar
• TSOU K, LOWITZ KA, HOHMANN AG et al: Suppression of noxious stimulus-evoked expression of fos protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience (1996) 70:791–798.
   PubMed Web of Science ®Google Scholar
• FRIDE E, MECHOULAM R: Pharmacological activity of the cannabinoid agonist, anandamide, a brain constituent. Eur.j Pharmacol (1993) 231:313–314.
   PubMed Web of Science ®Google Scholar
• CALIGNANO A, LA RANA G, GIUFFRIDA A, PIOMELLI D: Control of pain initiation by cannabinoids. Nature (1998) 396:277–281.
   Google Scholar
• ••First demonstration of the potential role of peripheral CB receptors in pain.
   Google Scholar
• RICHARDSON JD, KILO S, HARGREAVES KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CBI receptors. Pain (1998a) 75:111–119.
   PubMed Web of Science ®Google Scholar
• RICHARDSON JD, AANONSEN L, HARGREAVES KM: Antihyperalgesic effects of spinal cannabinoids. Eur. Pharmacol (19980 345:145–153.
   Google Scholar
• MARTIN WJ, LOO CM, BASBAUM Al: Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain (1999) 82:199–205.
   PubMed Web of Science ®Google Scholar
• LI J, DAUGHTERS RS, BULLIS C et al: The cannabinoid receptor agonist WIN-55212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain (1999) 81:25–33.
   PubMed Web of Science ®Google Scholar
• HERZBERG U, ELIAV E, BENNETT GJ, KOPIN IJ: The analgesic effects of R(+)-WIN-55212-2 mesylate, a high affinity cannabinoid agonist in a rat model of neuropathic pain. NeuroscL Lett. (1997) 221:157–160.
   PubMed Web of Science ®Google Scholar
• BRIDGES D, AHMAD K, RICE ASC: The synthetic cannabinoid WIN-55212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. BE J. Pharmacol (2001) 133:586–594.
   PubMed Web of Science ®Google Scholar
• FOX A, KESINGLAND A, GENTRY CG et al: The role of central and peripheral CBI receptors in the anti-hyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain (2001) 92:91–100.
   PubMed Web of Science ®Google Scholar
• •First indication of the role of peripheral CBI receptors in a model of neuropathic pain, providing a potential mechanism for analgesia with no central side effects.
   Google Scholar
• YAKSH TL: The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. Clin. Pharmcol (1981) 21:3345–3405.
   Google Scholar
• WELCH SP, HUFFMAN JW, LOWE J: Differential blockade of the antinociceptive effects of centrally administered cannabinoids by 5R141716A. Pharmacol Exp. Thar. (1998) 286:1301–1308.
   PubMed Web of Science ®Google Scholar
• MARTIN WJ, LAI NK, PATRICK SL, TSOU K, WALKER JM: Antinociceptive actions of cannabinoids following intraventricular administration in rats. Bran] Res. (1993) 629:300–304.
   PubMed Web of Science ®Google Scholar
• HOHMANN AG, TSOU K, WALKER JM: Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci. Lett. (1998) 257:119–122.
   PubMed Web of Science ®Google Scholar
• MARTIN WJ, PATRICK SL, COFFIN PO, TSOU K, Walker JM: An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. (1995) 56:2103–2110.
   PubMed Web of Science ®Google Scholar
• HOHMANN AG, TSOU K, WALKER JM: Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol (1999) 81:575–583.
   PubMed Web of Science ®Google Scholar
• JOHANEK LM, HEITMILLER DR, TURNER M, NADER N, HODGES J, SIMONE D: Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain (2001) 93:303–315.
   PubMed Web of Science ®Google Scholar
• STRANGMAN NM, WALKER JM: Cannabinoid WIN-55212-2 inhibits the activity dependent facilitation of spinal nociceptive responses. J. Neurophysiol (1999) 81:472–477.
   Google Scholar
• RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR-141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240–24.
   PubMed Web of Science ®Google Scholar
• LICHTMAN AH, MARTIN BR: The selective cannabinoid antagonist SR-141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem. Behav. (1997) 57:7–12.
   PubMed Web of Science ®Google Scholar
• JOHANEK LM, SOMONE DA: Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain (2004) 109:432–442.
   PubMed Web of Science ®Google Scholar
• HOHMANN AG, HERKENHAUM M: Localisation of cannabinoid (CBI) receptor mRNA in neuronal subpopulations of rat dorsal root ganglia: a double label in situ hybridisation study. Neuroscience (1999a) 90:923–931.
   PubMed Web of Science ®Google Scholar
• HOHMANN AG, HERKENHAUM M: Cannabinoid receptors undergo axonal flow in sensory nerves. Neurosci. (1999b) 92:1171–1175.
   PubMed Web of Science ®Google Scholar
• KELLY S, JHAVERI MD, SAGAR DR, KENDALL DA, CHAPMAN V: Activation of peripheral cannabinoid CBI receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation. Eur. NeuroscL (2003) 18:2239–2243.
   PubMed Web of Science ®Google Scholar
• MOSS S, NAEEM S, BEVAN S, FOX A: Cannabinoid inhibition of primary afferent nerve activity. Soc. Neuroscience abstracts (2003).
   Google Scholar
• ELLINGTON HC, COTTER MA, CEMERON NE, ROSS RA: The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats. Neuropharinacoi (2002) 42:966–975.
   PubMed Web of Science ®Google Scholar
• HUDSON LJ, BEVAN S, WOTHERSPOON G, GENTRY C, FOX A, WINTER J: VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur..I. Neurosci. (2001) 13:2105–2114.
   PubMed Web of Science ®Google Scholar
• HUDSON LJ, BEVAN S, McNAIR K et al.: Metabotropic glutaomate receptor 5 upregulation in A-fibres after spinal nerve injury: MPEP reduces the induced thermal hyperalgesia. ./. Neurosci. (2002) 22:2660–2668.
   PubMed Web of Science ®Google Scholar
• VERME JL, FU J, ASTARITA G et al: Thenuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharinacol. (2005) 67:15–19.
   PubMed Web of Science ®Google Scholar
• CLAYTON N, MARSHALL FH, BOUNTRA C, O'SHAUGHNESSY CT: CBI and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain (2002) 96:253–260.
   PubMed Web of Science ®Google Scholar
• HANUS L, BREUER A, TCHILIBON S et al.: HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor. Proc Nati Arad Sci (1999) 96:14228–14233.
   PubMed Web of Science ®Google Scholar
• QUARTILHO A, MATA HP, IBRAHIM MM et al: Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 99:955–960.
   PubMed Web of Science ®Google Scholar
• NACKLEY AG, ZVONOK AM, MAKRIYANNIS A, HOHMANN AG: Activation of cannabinoid CB2 receptors suppresses C-fiber responses and wind-up in spinal wide dynamic range neurons in the absence and presence of inflammation. Neurophysiol. (2004) 92:3562–3574.
   PubMed Web of Science ®Google Scholar
• SCOTT DA, WRIGHT CE, ANGUS JA: Evidence that CBI and CB2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Path (2004) 109:124–131.
   Google Scholar
• IBRAHIM MM, DENG H, ZVONOK A et al.: Activation of CB2 cannabiniod receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Nati Acad. Sci. (2003) 100:10529–10533.
   PubMed Web of Science ®Google Scholar
• •First demonstration of a potential role for CB2 receptors in neuropathic pain models.
   Google Scholar
• MALAN TP, IBRAHIM MM, DENG H et al: CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 93:239–245.
   PubMed Web of Science ®Google Scholar
• HOHMANN AG, FARTHING JN, ZVONOK AM, MAKRIYANNIS A: Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. I Phannacol. Exp. Ther. (2004) 308:446–453.
   PubMed Web of Science ®Google Scholar
• IBRAHIM MM, PORRECA F, LAI J et al:CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Li. (2005) 102:3093–3098.
   PubMed Web of Science ®Google Scholar
• NOYES R, BRUNK F, AVERY DH, CANTER A: The analgesic properties of A9-tetrahydrocannabinol and codeine. Clin. Phannaco. Ther. (1975) 18:84–89.
   PubMed Web of Science ®Google Scholar
• MARTYN CM: Nabilone in the treatmentof multiple sclerosis. Lancet (1995) 345:579.
   PubMed Web of Science ®Google Scholar
• CONSROE P, MUSTY R, REIN J, TILLERY W, PERT WEE R: The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. (1997) 38:44–48.
   PubMed Web of Science ®Google Scholar
• HAMMAN W, DI VADI PP: Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet (1999) 353:560.
   Web of Science ®Google Scholar
• CAMPBELL FA, TRAMER MR, CARROLL D, REYNOLDS DJM, MOORE RA, McQUAY HJ: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br. Med. J. (2001) 323:13–16.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis of early controlled clinical trials of cannabinoids in pain conditions. Results indicated analgesic activity, but doses were limited by CNS side effects.
   Google Scholar
• WADE DT, ROBSON P, HOUSE H, MAKELA P, ARAM J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. (2003) 17:21–29.
   PubMed Web of Science ®Google Scholar
• NOTCUTT W, PRICE M, MILLER R et al: Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia (2004) 59:440–452.
   PubMed Web of Science ®Google Scholar
• BERMAN JS, SYMONDS C, BIRCH R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. Path (2004) 112:299–306.
   Google Scholar
• ATTAL N, BRASSEUR L, GUIRIMAND D, CLERMOND-GNAMIEN S, ATLAMI S, BOUHASSIRA D: Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur. Path (2004) 8:173–177.
   Google Scholar
• ZAJICEK J, FOX P, SANDERS H et a/.:UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet (2003) 362:1517–1526.
   Google Scholar
• SVENDSEN KB, JENSEN TS, BACH FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br. Med. J. (2004) 329:253
   PubMed Web of Science ®Google Scholar
• SMITH PF: Medicinal cannabis extracts for the treatment of multiple sclerosis. Curt: Opinion Invest. Drugs (2004) 5: 727–730.
   PubMedGoogle Scholar
• ••Excellent review of the potential utility ofCBs in treating symptoms of multiple sclerosis.
   Google Scholar
• KARST M, SALIM K, BURSTEIN S, CONRAD I, HOY L, SCHNEIDER U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA (2003) 290: 1757-1762.
   Google Scholar
• ••Important study showing that a modifiedcannabinoid structure is analgesic in neuropathic pain patients, with no obvious central cannabis-like side effects.
   Google Scholar
• COMPTON DR, JOHNSON MR, MELVIN LS, MARTIN BR: Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. J. Pharinacol. Exp. Ther. (1992) 260:201–209.
   PubMed Web of Science ®Google Scholar
• LIM G, SUNG B, RONG R, MAO J: Upregulation of spinal cannabinoid-1 receptors following nerve injury enhances the effects of WIN55,212-2 on neuropathic pain behaviours in rats. Path (2003) 105:275–283.
   Google Scholar
• CICHEWICZ DL. McCARTHY EA: Antinociceptive synergy between A(9)-tetrahydrocannabinol and opioids after oral administration. I Pharmacol Exp. Thar. (2003) 304:1010–1015.
   PubMed Web of Science ®Google Scholar
• HOLD CROFT A, SMITH M, JACKLIN A et al.: Pain relief with oral cannabinoids in familial Mediterranean fever. Anaethesiology (1997) 52:483–486.
   Google Scholar
• MANZANARES J, CORCHERO J, ROMERO J, FERNADEZ-RUIZ JJ, RAMOS JA, FUENTES JA: Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol ScL (1999) 20:287–293.
   PubMed Web of Science ®Google Scholar
• MAO J, PRICE DD, LU J, KENISTON L,MAYER DJ: Two distinctive antinociceptive systems in rats with pathological pain. Neurosci. Lett (2000) 280:13–16.
   PubMed Web of Science ®Google Scholar
• WALKER JM, HUANG SM, STRANGMAN NM, TSOU K, SANUDO-PENA MC.: Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci (1999) 96:12198–12203.
   Google Scholar
• LICHTMAN AH, LEUNG D, SHELTON CC et al: Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. Pharmacol Exp. Then (2004a) 311:441–448.
   PubMed Web of Science ®Google Scholar
• LICHTMAN AH, SHELTON CC, ADVANI T, CRAVATT BF: Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Path (2004) 109:319–327.
   Google Scholar
• ZHANG J, HOFFERT C, VU HK, GROBLEWSKI T, AHMAD S, O'DONELL D: Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. Neurosci. (2003) 17:2750–2754.
   PubMed Web of Science ®Google Scholar
• •First indication that CB2 receptors may be expressed centrally during pain conditions. Thus, activity of CB2 selective agonists in chronic pain is not synonymous with a peripheral site of action.
   Google Scholar
• RUKWIED R, WATKINSON A, McGLONE F, DVORAK M: Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Path (2003) 102:283–288.
   Google Scholar
• ••Important study demonstrating thatfunctional CB receptors are present on peripheral sensory nerves in man.
   Google Scholar
• DVORAK M, WATKINSON A, McGLONE F, RUKWEID R: Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. In/lam. Res. (2003) 52:238–245.
   PubMed Web of Science ®Google Scholar
• BURSTEIN SH, FRIDERICHS E, KOGEL B, SCHNEIDER J, SELVE N: Analgesic effects of 1',1'-dimethylheptyl-E8-THC-11-oic acid (CT-3) in mice. Life ScL (1998) 63:161–168.
   PubMed Web of Science ®Google Scholar
• BURSTEIN SH, KARST M, SCHNEIDER U, ZURIER RB: Ajulemic acid: A novel cannabinoid produces analgesia without a 'high'. Lai. Sci. (2004) 75:1513–1522.
   PubMed Web of Science ®Google Scholar
• DAJANI EZ, LARSEN KR, TAYLOR J et aL:1', 1 '-Dimethylheptyl-A8-tetrahydrocannabino1-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. Pharmacol Exp. Thar. (1999) 291:31–38.
   PubMed Web of Science ®Google Scholar
• DYSON A, PEACOCK M, CHEN A et al: Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain (2005) (In Press).
   Google Scholar
• HERTZOG DL: Recent advances in the cannabinoids. Expert Opin. Then Patents (2002) 14:1435–1452.
   Web of Science ®Google Scholar
• FACCI L, DAL TOSO R, ROMANELLO S, BURIANI A, SKAPER SD, LEON A: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamine. Proc. Natl. Acad. Sci. USA (1995) 92:3376–3380.
   PubMed Web of Science ®Google Scholar
• RINALDI-CARMONA M, BARTH F, MILLAN J et al: SR-144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol Exp. Then (1998) 284:644–650.
   PubMed Web of Science ®Google Scholar
• ZURIER RB, ROSSETTI RG, LANE JH, GOLDBERG JM, HUNTER SA, BURSTEIN SH: Dimethylheptyl-THC-11-oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum. (1998) 41:163–170.
   PubMed Web of Science ®Google Scholar